Equities Analysts Offer Predictions for CHRN Q2 Earnings

ChronoScale Corporation Common Stock (NASDAQ:CHRN) – Equities research analysts at Northland Securities issued their Q2 2027 earnings estimates for ChronoScale Corporation Common Stock in a research note issued on Thursday, October 15th. Northland Securities analyst N. Chokshi expects that the company will earn ($0.07) per share for the quarter. Northland Securities currently has an “Outperform” rating and a $32.00 price target on the stock. Northland Securities also issued estimates for ChronoScale Corporation Common Stock’s Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.11) EPS, FY2027 earnings at ($0.39) EPS, Q1 2028 earnings at ($0.05) EPS, Q2 2028 earnings at ($0.24) EPS, Q3 2028 earnings at ($0.02) EPS, Q4 2028 earnings at $0.16 EPS and FY2028 earnings at ($0.15) EPS.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last released its earnings results on Wednesday, October 14th. The company reported ($0.29) earnings per share (EPS) for the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. The company had revenue of $41.48 million during the quarter.

Separately, Weiss Ratings upgraded shares of ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, October 9th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, ChronoScale Corporation Common Stock has an average rating of “Hold” and an average target price of $19.00.

ChronoScale Corporation Common Stock Stock Up 7.9%

Shares of NASDAQ CHRN opened at $16.05 on Friday. The stock has a fifty day moving average price of $19.90 and a 200 day moving average price of $18.19. The company has a current ratio of 0.51, a quick ratio of 0.51 and a debt-to-equity ratio of 0.06. ChronoScale Corporation Common Stock has a 12-month low of $3.50 and a 12-month high of $30.00. The company has a market cap of $2.34 billion, a P/E ratio of -2.98 and a beta of 0.98.

Institutional Inflows and Outflows

An institutional investor recently raised its position in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc boosted its position in shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN) by 104.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,338 shares of the company’s stock after purchasing an additional 1,195 shares during the period. Roble Belko & Company Inc owned 0.07% of ChronoScale Corporation Common Stock worth $25,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.42% of the company’s stock.

Trending Headlines about ChronoScale Corporation Common Stock

Here are the key news stories impacting ChronoScale Corporation Common Stock this week:

• Positive Sentiment: Northland Securities’ outlook implies significant potential appreciation, with the firm retaining its Outperform rating and $32 target. The analyst forecasts a return to quarterly profitability with $0.16 EPS in Q4 2028, suggesting improving earnings power over time. Northland Securities analyst estimates
• Neutral Sentiment: Northland expects ChronoScale to remain unprofitable across the forecast period, including estimated losses of $0.07 per share in Q2 2027, $0.10 in Q3 2027, $0.39 for fiscal 2027, and $0.15 for fiscal 2028. The estimates indicate a gradual path toward profitability but continued execution risk. ChronoScale earnings estimates
• Negative Sentiment: ChronoScale reported a fiscal first-quarter loss of $0.29 per share on $41.48 million in revenue. Its negative net margin of 135.66% and negative return on equity of 197.81% underscore substantial ongoing losses and may weigh on the stock until growth translates into better profitability. ChronoScale Reports Fiscal First Quarter 2027 Results

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.